Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean M Wingerchuk

Showing results (151-160 of 184) with videos related to

Pageof 19
Sort By:
Neurology|June 13, 2022
Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSDShailee S Shah, Pearse Morris, Marina Buciuc, et al.
Archives of Neurology|September 10, 2008
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patientsAnu Jacob, Brian G Weinshenker, Ivo Violich, et al.
Stroke|January 11, 2021
Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute MyelitisElia Sechi, Sara Mariotto, Andrew McKeon, et al.
Archives of Neurology|April 18, 2012
Effects of age and sex on aquaporin-4 autoimmunityAmy M L Quek, Andrew McKeon, Vanda A Lennon, et al.
Annals of Neurology|February 15, 2021
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSDDean M Wingerchuk, Kazuo Fujihara, Jacqueline Palace, et al.
Multiple Sclerosis and Related Disorders|March 6, 2021
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extensionHo Jin Kim, Ichiro Nakashima, Shanthi Viswanathan, et al.
JAMA Neurology|November 20, 2013
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitisYujuan Jiao, James P Fryer, Vanda A Lennon, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 11, 2024
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum DisorderAlessandro Dinoto, Laura Cacciaguerra, Karl N Krecke, et al.
The New England Journal of Medicine|May 4, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum DisorderSean J Pittock, Achim Berthele, Kazuo Fujihara, et al.
Multiple Sclerosis and Related Disorders|December 14, 2020
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trialJacqueline Palace, Dean M Wingerchuk, Kazuo Fujihara, et al.
Pageof 19

Showing results (151-160 of 184) with videos related to

Sort By:
Pageof 19
Neurology|June 13, 2022
Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSDShailee S Shah, Pearse Morris, Marina Buciuc, et al.
Archives of Neurology|September 10, 2008
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patientsAnu Jacob, Brian G Weinshenker, Ivo Violich, et al.
Stroke|January 11, 2021
Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute MyelitisElia Sechi, Sara Mariotto, Andrew McKeon, et al.
Archives of Neurology|April 18, 2012
Effects of age and sex on aquaporin-4 autoimmunityAmy M L Quek, Andrew McKeon, Vanda A Lennon, et al.
Annals of Neurology|February 15, 2021
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSDDean M Wingerchuk, Kazuo Fujihara, Jacqueline Palace, et al.
Multiple Sclerosis and Related Disorders|March 6, 2021
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extensionHo Jin Kim, Ichiro Nakashima, Shanthi Viswanathan, et al.
JAMA Neurology|November 20, 2013
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitisYujuan Jiao, James P Fryer, Vanda A Lennon, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 11, 2024
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum DisorderAlessandro Dinoto, Laura Cacciaguerra, Karl N Krecke, et al.
The New England Journal of Medicine|May 4, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum DisorderSean J Pittock, Achim Berthele, Kazuo Fujihara, et al.
Multiple Sclerosis and Related Disorders|December 14, 2020
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trialJacqueline Palace, Dean M Wingerchuk, Kazuo Fujihara, et al.
Pageof 19